US › Healthcare

CytoMed Therapeutics Limited Ordinary Shares (GDTC)

US · Healthcare · Biotechnology

$0.85-7.30%

Last close · 2026-08-04

Latest quarter · ended 2025-12-31

Revenue

$167,945

Revenue YoY

+18.5%

Net profit

$-1.7M

Profit YoY

-138.8%

EPS

$0.00

EPS estimate

$-0.04

Net margin

-1,030.7%

EPS came in at 0.00 against a street estimate of -0.04 — a beat of 100.0%.

Key statistics

Market cap

$11.0M

Forward P/E

0.0

P/B

2.17

Book value

$0.43

EPS (TTM)

$-0.26

52-week high

$3.68

52-week low

$0.68

50-day MA

$1.05

200-day MA

$1.28

Beta

0.02

Analyst view

Analysts rate CytoMed Therapeutics Limited Ordinary Shares a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $5.00.

Shareholding

Insiders

70.47%

Institutions

0.24%

Largest institutional holders

Fund	Stake
XTX Topco Ltd	0.09%
UBS Group AG	0.05%
Advisor Group Holdings, Inc.	0.00%
StoneX Group Inc	0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for CytoMed Therapeutics Limited Ordinary Shares — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.